Method Specific

Intrauterine Contraception

FSRH Clinical Guideline: Intrauterine Contraception (April 2015, amended September 2019)

26 September 2019

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of intrauterine contraception (IUC) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. This guideline was updated in September 2019.

This document is up-to-date

Progestogen-only Implants

FSRH Clinical Guideline: Progestogen-only Implant (February 2014)

01 February 2014

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

15 January 2020

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

This document is up-to-date

Progestogen-only Injectables

FSRH Clinical Guideline: Progestogen-only Injectable (December 2014, Amended June 2020)

24 June 2020

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

Progestogen-only Pills

FSRH Clinical Guideline: Progestogen-only Pills (March 2015, Amended April 2019)

30 April 2019

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only pills currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

Combined Hormonal Contraception

FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended July 2019)

01 February 2019

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of combined hormonal contraceptives (i.e. the combined oral contraceptive pill, transdermal patch and combined vaginal ring) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

This document is up-to-date

FSRH CEU Guidance: Combined Hormonal Contraception Quick Reference Summary (January 2019)

01 January 2019

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on combined hormonal contraception (CHC). Please refer to the full 2018 FSRH CHC Clinical Guideline for further information and evidence for this advice. This document is written for FSRH members and requires you to log in to access it.

This document is up-to-date

FSRH CEU Guidance: Recommended Actions after incorrect Use of Combined Hormonal Contraception (e.g. late or missed pills, ring and patch) (March 2020)

16 March 2020

This document provides guidance on incorrect use of: combined oral contraceptive pills, the combined vaginal ring, and the combined transdermal patch. The guideline was developed with a team of international experts and has been extensively peer reviewed in accordance with methodology used for developing FSRH Clinical Guidelines. The guidance is intended for use by health professionals working in SRH, general practice and obstetric and gynaecology settings, and can also be used by women using CHC. Download the document here.

This document is up-to-date

FSRH CEU Statement: Strengthening of Warnings about use of Dianette and other brands of co-cyprindiol (June 2013)

01 June 2013

Following a recent safety review, a letter has been issued to healthcare professionals from the manufacturers of Dianette® and other cyproterone acetate 2 mg/ ethinylestradiol 35 mcg (co-cyprindiol) products. The review by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) followed concerns about the risk of thrombosis associated with co-cyprindiol. With the agreement of the EMA and Medicines and Healthcare products Regulatory Authority (MHRA), a letter has been issued to raise awareness of the thrombosis risks and the outcome of the review.

This document is up-to-date

Barrier Methods

FSRH Clinical Guideline: Barrier Methods for Contraception and STI Prevention (August 2012, amended October 2015)

01 October 2015

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of barrier methods for contraception and STI prevention. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

Male and Female Sterilisation

FSRH Clinical Guideline: Male and Female Sterilisation (September 2014)

01 September 2014

This guidance provides evidence-based recommendations and good practice points for health professionals on elective male sterilisation (vasectomy) and female sterilisation (tubal occlusion) in the UK. It is intended for any health care professional or service that undertakes or refers individuals for either procedure. This guidance has been jointly developed with the Royal College of Obstetricians and Gynaecologists (RCOG).

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH CEU Statement: Response to the BMJ paper by Mao et. al. (October 2015)

01 October 2015

A large observational study from the United States found that the risk of unintended pregnancy after Essure sterilisation was similar to that after surgical sterilisation. However just over 2% of women who had Essure sterilisation required a further operation related to the sterilisation procedure within a year.

This document is up-to-date

Fertility Awareness Methods

FSRH Clinical Guideline: Fertility Awareness Methods (June 2015)

01 June 2015

This is a new guidance document that provides evidence-based recommendations and good practice points on the use of fertility awareness methods (FAM) for the purpose of preventing and/or spacing pregnancies. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

Other